Canada Markets open in 1 hr 12 mins

Mesoblast Limited (MESO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.21-0.26 (-4.75%)
At close: 04:00PM EST
4.85 -0.36 (-6.91%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close5.47
Open5.47
Bid5.19 x 1100
Ask5.50 x 1000
Day's Range5.13 - 5.54
52 Week Range5.13 - 17.37
Volume192,094
Avg. Volume134,041
Market Cap657.768M
Beta (5Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia

    Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma Industry Drugs Approved for Cardiovascular Risk Reduction in DiabetesKey points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest treatment benefit in major adverse cardiovascular events (MACE) of cardiovascular mortality or irreversible morbidity (non-fatal heart attack or str

  • GlobeNewswire

    Operational Highlights and Financial Results for the Period Ended September 30, 2021

    NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the first quarter ended September 30, 2021. “We are pleased to have entered into a strategic financing partnership with leading global investment management firm Oaktree Capital as we focus on bringing our first product to the US market and in line with our commercial growth

  • GlobeNewswire

    Mesoblast Corporate Update and Financial Results Webcast

    NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the first quarter ended September 30, 2021. The webcast will begin at 5.00pm EST, Tuesday, November 23; 9.00am AEDT, Wednesday, November 24, 2021. It can be accessed via: https://webcast.openbriefing.com/8205/ The archived webcast will be available on the Inve